Published online Jul 26, 2022. doi: 10.12998/wjcc.v10.i21.7467
Peer-review started: November 24, 2021
First decision: April 13, 2022
Revised: April 28, 2022
Accepted: June 3, 2022
Article in press: June 3, 2022
Published online: July 26, 2022
Processing time: 229 Days and 4.5 Hours
Although tumors of the lacrimal sac are rare, they represent a potentially life-threatening situation that can easily be overlooked since patients present with features consistent with chronic dacryocystitis. Lacrimal sac squamous cell carcinoma is the most common lacrimal sac malignancy, but no definitive treatment is currently available.
We describe a 34-year-old unmarried male who presented with a red and swollen right lower eyelid, which gradually developed into a mass of the lower eyelid that obstructed vision in his right eye. He was treated with transcatheter arterial infusion chemotherapy and interventional embolization based on the tumor characteristics, and we also administered intensity-modulated radiotherapy and targeted therapy after tumor shrinkage. The tumor treatment demonstrated good efficacy, and the patient’s condition was stable after 10 mo of follow-up.
To our knowledge, this is the first report of lacrimal sac squamous cell carcinoma treated with transcatheter arterial infusion chemotherapy and interventional embolization, which might expand clinical treatment options for lacrimal sac carcinoma.
Core Tip: Tumors of the lacrimal sac are extremely rare but are potentially devastating lesions that lack an effective remedy. We present a case of lacrimal sac squamous cell carcinoma that was treated with transcatheter arterial infusion chemotherapy and interventional embolization to provide a reference for the treatment of primary lacrimal sac tumors.